Our data demonstrated that, there were no significant change in the levels of RANKL, OPG, RANKL/OPG in D2M2-treated group compared to those in the anti-CD3/CD28 group in RA (P > 0.05; Table 5, Figures 1, 5, and 6). This evidence concerns the gene CD28 and rheumatoid arthritis.